Search

Your search keyword '"Bando, Masashi"' showing total 25 results
Start Over Author "Bando, Masashi" Publisher japanese society of internal medicine
25 results on '"Bando, Masashi"'

3. Progression of Central-peripheral Band and Traction Bronchiectasis Clusters Leading to Chronic Respiratory Failure in a Patient with Fibrotic Pulmonary Sarcoidosis

Author

Sawahata, Michiru, primary, Shijubo, Noriharu, additional, Johkoh, Takeshi, additional, Kawanobe, Takeshi, additional, Fujiki, Yasumaro, additional, Bando, Masashi, additional, Hagiwara, Koichi, additional, Takemura, Tamiko, additional, Konno, Satoshi, additional, and Yamaguchi, Tetsuo, additional

Published
2021
Full Text
View/download PDF

24. Paradoxical Formation of a Pleuroparenchymal Fibroelastosis-like Lesion in the Chronic Course of Pulmonary Sarcoidosis.

Author

Sawahata M, Johkoh T, Kawanobe T, Kono C, Suzuki T, Bando M, Hagiwara K, Shijubo N, Konno S, and Yamaguchi T

Subjects
Adult, Biopsy, Humans, Lung diagnostic imaging, Lung pathology, Male, Tomography, X-Ray Computed methods, Lung Diseases pathology, Sarcoidosis, Pulmonary diagnostic imaging, Sarcoidosis, Pulmonary pathology
Abstract

We herein report the long-term changes in chest computed tomography (CT) findings from early sarcoidosis lesions to pleuroparenchymal fibroelastosis (PPFE)-like lesions in a 30-year-old man with granulomas on a transbronchial lung biopsy. Multiple bilateral micronodular and nodular opacities around the bronchovascular bundle in the upper lobes detected by chest CT in 2004 disappeared, but paradoxically, peripheral consolidations continued to grow at the periphery of the original lesions. Chest CT in 2017 confirmed the progression of bilateral shrinkage of the upper lobe, spread of peripheral consolidations and wedge-shaped opacities below the first rib, and bronchiectatic air bronchograms, confirming PPFE-like lesions.

Published
2022
Full Text
View/download PDF

25. Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Author

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Homma S, and Sugiyama Y

Subjects
Aged, Disease Progression, Dose-Response Relationship, Drug, Female, Humans, Idiopathic Pulmonary Fibrosis physiopathology, Japan epidemiology, Male, Retrospective Studies, Time Factors, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Idiopathic Pulmonary Fibrosis drug therapy, Pyridones administration & dosage, Vital Capacity drug effects
Abstract

Objective: Long-term effects of pirfenidone have been poorly understood to date. This study investigated the clinical efficacy and safety of long-term pirfenidone use for idiopathic pulmonary fibrosis (IPF) in clinical practice., Methods: This survey study was a retrospective observational study. A survey was used to collect clinical information on IPF cases that were treated with pirfenidone. This survey sheet came from physicians belonging to the Diffuse Lung Diseases Research Group., Results: 502 patients at 22 institutes received pirfeidone treatment. Of the 502 cases, pirfenidone treatment was terminated in under one year in 186 cases (37.1%); adverse effect was the most frequent reason for termination. The pirfenidone treatment lasted for two years or longer in 111 cases (22.1%). The mean change in the forced vital capacity (FVC) was -30±224 (SD) mL in the first year of treatment, -158±258 mL in the second year, and -201±367 mL in the third year. FVC improved by 10% or more in the first year in 10 (14.7%) of 68 cases, and showed a change of ±10% in 47 (69.1%) cases. It showed a change of ±10% in the second and third years in 61.7% and 62.5% of the patients, respectively., Conclusion: The FVC improved in only a small percentage of patients who received pirfenidone treatment for a long period of time. However, a decrease in the FVC was prevented for three years in over half of the cases.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results